FAR09

FAR09 is an experimental small molecule androgen receptor (AR) antagonist. It belongs to a series of 4,4-dimethylimidazolidin-2-one pharmacophore-based compounds (FAR01-FAR11) designed as flexible analogs of the second-generation AR antagonist enzalutamide. In these molecules, the rigid thiohydantoin ring found in enzalutamide is replaced by a more flexible 4,4-dimethylimidazolidin-2-one moiety, and a methylene group is introduced between the pharmacophore and one of the aromatic rings to further enhance flexibility. FAR09 was developed to target AR signaling, which is a fundamental driver of tumour growth in prostate cancer, including castration-resistant prostate cancer (CRPC). The compound has been evaluated in vitro using the androgen-dependent LNCaP prostate cancer cell line to assess its potential as a therapeutic agent for androgen deprivation therapy (ADT).